• Vaccine for children arriving in December: no obligation, no green pass

  • Magrini, Aifa: from 29 November decision on vaccine for children, after Christmas the anti Covid pill


November 25, 2021 The European Medicines Agency (EMA) has approved the extension of the use of BioNTech-Pfizer's Covid-19 vaccine for children between the ages of 5 and 11. The vaccine, developed by BioNTech and Pfizer, is already approved for use in adults and children aged 12 and above. "In children 5 to 11 years of age, the dose of Comirnaty will be lower than that used in people 12 years of age and older (10 micrograms versus 30 micrograms). As in the older age group, it is given with two injections into the muscles of the upper arm, three weeks apart ", explains the EMA in a note.

"The effectiveness of Comirnaty was calculated in nearly 2,000 children between the ages of 5 and 11 who did not have any previous signs of infection. These children received the vaccine or a placebo. Of the 1,305 children who received the vaccine, three developed Covid-19 compared to 16 of the 663 children who received the placebo. This means that, in this study, the vaccine was 90.7% effective in preventing symptomatic Covid-19 (although the actual rate could be between 67.7% and 98.3%) ", concluded the EMA.